This mechanism provides a potential explanation for the harmful effects of intensive insulin treatment observed in T2D patients, suggesting GRK2 and β2AR as potential promising pharmacological targets for the treatment of cardiomyopathy in T2D. This evidence concerns the gene INS and type 2 diabetes mellitus.